An evaluation of bimekizumab for the treatment of hidradenitis suppurativa.

IF 3.6 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2025-06-17 DOI:10.1080/14712598.2025.2522119

Tomasz Skrzypczak, Anna Skrzypczak, Łukasz Matusiak, Jacek C Szepietowski

{"title":"An evaluation of bimekizumab for the treatment of hidradenitis suppurativa.","authors":"Tomasz Skrzypczak, Anna Skrzypczak, Łukasz Matusiak, Jacek C Szepietowski","doi":"10.1080/14712598.2025.2522119","DOIUrl":null,"url":null,"abstract":"Introduction: Until recently, the biological treatment options for hidradenitis suppurativa (HS) were largely restricted to adalimumab and secukinumab. In 2024, bimekizumab, an IL-17A and IL-17F antibody was introduced to the clinical practice.Areas covered: Bimekizumab offers a new therapeutic approach for managing HS. It was approved by the U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2024. The available biologic therapies in HS treatment are described. The data from phase II and phase III clinical trials were analyzed to evaluate the bimekizumab effectiveness in HS treatment. Data from those trials and latest summaries of product characteristics (SmPC) were retrieved to investigate its safety profile. The current preliminary data regarding its long-term effectiveness from BE HEARD EXT (NCT04901195) trial were presented.Expert opinion: The common side effects of bimekizumab were upper respiratory infections, candida infections and eczematous reactions across all indications. The favorable side effects profile and strong clinical effectiveness proved in clinical trials gave the bimekizumab potential to become the first-choice drug in HS treatment.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2025.2522119","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Until recently, the biological treatment options for hidradenitis suppurativa (HS) were largely restricted to adalimumab and secukinumab. In 2024, bimekizumab, an IL-17A and IL-17F antibody was introduced to the clinical practice.

Areas covered: Bimekizumab offers a new therapeutic approach for managing HS. It was approved by the U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2024. The available biologic therapies in HS treatment are described. The data from phase II and phase III clinical trials were analyzed to evaluate the bimekizumab effectiveness in HS treatment. Data from those trials and latest summaries of product characteristics (SmPC) were retrieved to investigate its safety profile. The current preliminary data regarding its long-term effectiveness from BE HEARD EXT (NCT04901195) trial were presented.

Expert opinion: The common side effects of bimekizumab were upper respiratory infections, candida infections and eczematous reactions across all indications. The favorable side effects profile and strong clinical effectiveness proved in clinical trials gave the bimekizumab potential to become the first-choice drug in HS treatment.

查看原文本刊更多论文

比美珠单抗治疗化脓性汗腺炎的评价。

导论：直到最近，化脓性汗腺炎（HS）的生物治疗选择在很大程度上仅限于阿达木单抗和secukinumab。2024年，一种IL-17A和IL-17F抗体bimekizumab被引入临床实践。涵盖领域：比美珠单抗为管理HS提供了一种新的治疗方法。它于2024年获得美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）的批准。介绍了HS治疗中可用的生物疗法。分析了II期和III期临床试验的数据，以评估比美珠单抗治疗HS的有效性。这些试验的数据和最新的产品特性摘要（SmPC）被检索，以调查其安全性概况。目前来自BE HEARD EXT （NCT04901195）试验的初步数据显示其长期有效性。专家意见：比美珠单抗的常见副作用是上呼吸道感染、念珠菌感染和湿疹反应。临床试验证明，比美珠单抗良好的毒副作用和强大的临床疗效，使其有可能成为治疗HS的首选药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.